[go: up one dir, main page]

MX2016013323A - Uso medico de compuestos de artemisinina y agonistas de gefirina. - Google Patents

Uso medico de compuestos de artemisinina y agonistas de gefirina.

Info

Publication number
MX2016013323A
MX2016013323A MX2016013323A MX2016013323A MX2016013323A MX 2016013323 A MX2016013323 A MX 2016013323A MX 2016013323 A MX2016013323 A MX 2016013323A MX 2016013323 A MX2016013323 A MX 2016013323A MX 2016013323 A MX2016013323 A MX 2016013323A
Authority
MX
Mexico
Prior art keywords
gephyrin
medical use
agonists
artemisinin compounds
artemisinin
Prior art date
Application number
MX2016013323A
Other languages
English (en)
Other versions
MX375933B (es
Inventor
Li Jin
Kubicek Stefan
Original Assignee
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cemm - Forschungszentrum Für Molekulare Medizin Gmbh filed Critical Cemm - Forschungszentrum Für Molekulare Medizin Gmbh
Publication of MX2016013323A publication Critical patent/MX2016013323A/es
Publication of MX375933B publication Critical patent/MX375933B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a aglutinantes BTBD9 y aglutinantes de gefirina para uso médico, y en particular a un compuesto artemisinina de fórmula general I para su uso en el tratamiento de un paciente diabético, así como un método de identificación de principales candidatos adecuados.
MX2016013323A 2014-04-11 2015-04-09 Uso medico de compuestos de artemisinina y agonistas de gefirina. MX375933B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14164471.6A EP2929881A1 (en) 2014-04-11 2014-04-11 Medical use of artemisinin compounds and gephyrin agonists
PCT/EP2015/057755 WO2015155303A2 (en) 2014-04-11 2015-04-09 Medical use of artemisinin compounds and gephyrin agonists

Publications (2)

Publication Number Publication Date
MX2016013323A true MX2016013323A (es) 2017-04-27
MX375933B MX375933B (es) 2025-03-07

Family

ID=50513025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013323A MX375933B (es) 2014-04-11 2015-04-09 Uso medico de compuestos de artemisinina y agonistas de gefirina.

Country Status (23)

Country Link
US (1) US9999621B2 (es)
EP (2) EP2929881A1 (es)
JP (1) JP6680759B2 (es)
KR (1) KR20160136452A (es)
CN (1) CN106459079B (es)
AU (1) AU2015245523A1 (es)
BR (1) BR112016023607A2 (es)
CA (1) CA2945046A1 (es)
CY (1) CY1122185T1 (es)
DK (1) DK3129019T3 (es)
ES (1) ES2749074T3 (es)
HR (1) HRP20191795T1 (es)
HU (1) HUE046397T2 (es)
IL (1) IL248259A0 (es)
LT (1) LT3129019T (es)
MX (1) MX375933B (es)
PL (1) PL3129019T3 (es)
PT (1) PT3129019T (es)
RS (1) RS59476B1 (es)
RU (1) RU2016144173A (es)
SI (1) SI3129019T1 (es)
SM (1) SMT201900560T1 (es)
WO (1) WO2015155303A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107349198A (zh) * 2016-05-10 2017-11-17 复旦大学 蒿甲醚在制备促进脂肪分解和改善糖代谢制剂中的用途
CN108383851A (zh) * 2016-12-09 2018-08-10 新乡学院 一种具有心脑血管疾病防治活性的青蒿素酯类化合物、其制备方法及其应用
WO2018115012A1 (en) * 2016-12-20 2018-06-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of neurodegeneration with brain iron accumulation
WO2019153325A1 (zh) * 2018-02-12 2019-08-15 深圳市中医院 青蒿素衍生物在制备预防和治疗2型糖尿病及其并发症药物中的应用及药物组合物
CN108403686A (zh) * 2018-02-12 2018-08-17 深圳市中医院 青蒿素衍生物在制备预防和治疗2型糖尿病及其并发症药物中的应用及药物组合物
CN108354927A (zh) * 2018-03-29 2018-08-03 上海壹志医药科技有限公司 蒿乙醚的新药物用途
CN109331012A (zh) * 2018-11-02 2019-02-15 广州中医药大学(广州中医药研究院) 青蒿素衍生物在制备抗癫痫药物中的应用
CN110200980B (zh) * 2019-05-13 2022-07-12 华南师范大学 一种荷载青蒿素的柑橘果胶的口服纳米粒子
CN110938080A (zh) * 2019-08-15 2020-03-31 恩施硒禾生物科技有限公司 一种青蒿琥酯的制备方法
KR102524408B1 (ko) * 2020-08-19 2023-04-21 주식회사 노브메타파마 아모디아퀸 및 아르테수네이트계 약물을 유효성분으로 함유하는 제2형 당뇨병 예방 또는 치료용 약학적 조성물
WO2022159581A2 (en) * 2021-01-20 2022-07-28 Cornell University Artemisinin-proteasome inhibitor conjugates and their use in the treatment of disease
CN114807015B (zh) * 2022-05-20 2022-11-22 呈诺再生医学科技(北京)有限公司 一种促进胰岛α细胞转化为β细胞的诱导方法及其应用
CN118526484A (zh) * 2024-07-26 2024-08-23 中国中医科学院中药研究所 青蒿琥酯或双氢青蒿素在制备改善罗格列酮不良反应制剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362810B1 (en) * 1988-10-07 1993-05-05 Hoechst Aktiengesellschaft Antimalarial compositions using quinidine, artemisinine and its derivatives
EP1978028A1 (en) * 2007-04-05 2008-10-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of gene variants of the human MEIS1, BTBD9, MAP2K5, LBXCOR1, PTPRD or A2BP1 gene for diagnostic and therapeutic approaches to restless legs syndrome (RLS)
US20100151056A1 (en) * 2008-12-16 2010-06-17 Hanan Polansky Dietary supplements for decreasing the latent foreign dna load
CN101879158B (zh) * 2010-07-01 2012-02-29 中国科学院广州生物医药与健康研究院 青蒿素衍生物的新应用
KR101277710B1 (ko) * 2010-09-07 2013-06-24 연세대학교 산학협력단 신규한 아테미시닌 또는 디옥소아테미시닌-당지질 복합유도체 및 그의 혈관신생억제 용도
WO2014007853A1 (en) * 2012-07-03 2014-01-09 The Regents Of The University Of California Dihydromyricetin for the treatment of diseases and disorders of the glutamatergic system
EP2900820B2 (en) * 2012-09-27 2020-11-18 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for producing a population of pancreatic beta-cells

Also Published As

Publication number Publication date
MX375933B (es) 2025-03-07
CN106459079A (zh) 2017-02-22
CA2945046A1 (en) 2015-10-15
CN106459079B (zh) 2019-09-24
PT3129019T (pt) 2019-10-28
WO2015155303A2 (en) 2015-10-15
HUE046397T2 (hu) 2020-03-30
RU2016144173A3 (es) 2018-12-03
IL248259A0 (en) 2016-11-30
EP3129019A2 (en) 2017-02-15
LT3129019T (lt) 2019-11-11
KR20160136452A (ko) 2016-11-29
SMT201900560T1 (it) 2019-11-13
US20170027929A1 (en) 2017-02-02
US9999621B2 (en) 2018-06-19
EP2929881A1 (en) 2015-10-14
EP3129019B1 (en) 2019-07-17
HRP20191795T1 (hr) 2019-12-27
SI3129019T1 (sl) 2019-11-29
AU2015245523A1 (en) 2016-11-03
RS59476B1 (sr) 2019-12-31
CY1122185T1 (el) 2020-11-25
ES2749074T3 (es) 2020-03-19
PL3129019T3 (pl) 2020-01-31
JP2017513936A (ja) 2017-06-01
WO2015155303A3 (en) 2016-02-04
BR112016023607A2 (pt) 2017-12-26
RU2016144173A (ru) 2018-05-11
DK3129019T3 (da) 2019-10-07
JP6680759B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
MX2016013323A (es) Uso medico de compuestos de artemisinina y agonistas de gefirina.
EP3558324A4 (en) CYCLIC STING DINUCLEOTID AGONISTS FOR CANCER TREATMENT
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CL2018000685A1 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
AR102712A1 (es) Agonistas parciales del receptor de insulina
CL2017003404A1 (es) Compuestos antibacterianos
AR101905A1 (es) Compuestos bicíclicos
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
MX2021008376A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CL2016001911A1 (es) Compuesto heterocíclico fusionado
AR089993A1 (es) Macrociclos peptidomimeticos
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
UY34648A (es) Amidas como inhibidores de pim
UY36445A (es) Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi)
EA201692219A1 (ru) Способы получения противовирусных соединений
BR112016025132A2 (pt) compostos polifluorados agindo como inibidores de tirosina quinase de bruton
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY35500A (es) Indazoles sustituidos con heteroarilo
CL2012003588S1 (es) Utensilio de proteccion para utilizar como traje quirurgico o de laboratorio
UY34097A (es) Alineación de anticoagulante de cebado para extracción de sangre.
GT201400162A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas

Legal Events

Date Code Title Description
FG Grant or registration